INBX
Inhibrx Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$121.17
−0.89%Jul 16, 2026, 13:00 UTC
Inhibrx entered into an amended loan agreement with Oxford Finance, expanding the total facility to $500.0 million and receiving an initial $100.0 million tranche.
Source:Jun 15, 2026, 13:15 UTC
Inhibrx announced that the U.S. FDA accepted for filing its Biologics License Application for ozekibart to treat unresectable or metastatic conventional chondrosarcoma.
Source: